Literature DB >> 11266426

Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains.

M J Rodríguez-Hernández1, L Cuberos, C Pichardo, F J Caballero, I Moreno, M E Jiménez-Mejías, A García-Curiel, J Pachón.   

Abstract

Sulbactam and imipenem were compared in an experimental pneumonia model in immunocompetent mice, using a susceptible strain of Acinetobacter baumannii, and in an experimental endocarditis model in rabbits, using an intermediately susceptible strain. In the former, sulbactam was as efficacious as imipenem in terms of survival, sterility of lungs and in the bacterial clearance from lungs and blood, provided that the t > MIC for sulbactam (1.84 h) was similar to that for imipenem (2.01 h). In the endocarditis model, imipenem (t > MIC, 2.12 h) was more efficacious than sulbactam (t > MIC, 1.17 h) in bacterial clearance from vegetations. These results show the efficacy of sulbactam in infections caused by susceptible strains of A. baumannii, with an MIC up to 4 mg/L, provided that doses reach a t > MIC similar to that of imipenem. The activity of sulbactam was time dependent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266426     DOI: 10.1093/jac/47.4.479

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  22 in total

1.  The increasing role of Acinetobacter species as nosocomial pathogens.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Curr Infect Dis Rep       Date:  2007-10       Impact factor: 3.725

2.  Pharmacodynamics modeling to optimize dosage regimens of sulbactam.

Authors:  Sutep Jaruratanasirikul; Wibul Wongpoowarak; Nanchanit Aeinlang; Monchana Jullangkoon
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

Review 3.  Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.

Authors:  P Poulikakos; G S Tansarli; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-16       Impact factor: 3.267

4.  Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.

Authors:  G Kalin; E Alp; A Akin; R Coskun; M Doganay
Journal:  Infection       Date:  2013-07-05       Impact factor: 3.553

Review 5.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

6.  Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.

Authors:  Jun Yong Choi; Chang Oh Kim; Yoon Seon Park; Hee Jung Yoon; So Youn Shin; Young Keun Kim; Myung Soo Kim; Yeon-A Kim; Young Goo Song; Dongeun Yong; Kyungwon Lee; June Myung Kim
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

7.  In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

Authors:  Paul G Higgins; Hilmar Wisplinghoff; Danuta Stefanik; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 8.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

9.  Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.

Authors:  Sutep Jaruratanasirikul; Wibul Wongpoowarak; Thitima Wattanavijitkul; Waroonrat Sukarnjanaset; Maseetoh Samaeng; Monchana Nawakitrangsan; Natnicha Ingviya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii.

Authors:  Alejandro Beceiro; Rafael López-Rojas; Juan Domínguez-Herrera; Fernando Docobo-Pérez; Germán Bou; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.